Anti-inflammatory agent 122

Anti-inflammatory agent 122 (Compound d12) (10-20 μM; 24 h) exhibits no obvious cytotoxicity against RAW264.7 macrophages at concentrations of 10 μM and 20 μM, with cell viability maintained at >80% under both concentrations^[1].
Anti-inflammatory agent 122 (2.5-10 μM; 1 h) dose-dependently downregulates LPS-induced iNOS and COX-2 expression, and inhibits the activation of JNK/p38/ERK MAPK pathway and p65/IκB NF-κB pathway in RAW264.7 macrophages^[1].
Anti-inflammatory agent 122 (0.6125-20 μM; 1 h) potently inhibits LPS-induced NO production in RAW264.7 macrophages, with an IC₅₀ of 3.96 μM and an inhibition rate of 88.04% at a concentration of 10 μM^[1].
Anti-inflammatory agent 122 modulates gene expression in lipopolysaccharide (LPS)-stimulated RAW264.7 macrophages, and exerts anti-inflammatory effects primarily by inhibiting the MAPK and TNF signaling pathways^[1].
Anti-inflammatory agent 122 (1.25-20 μM; 1 h) dose-dependently inhibits LPS-induced TNF-α and IL-1β secretion in RAW264.7 macrophages, with IC₅₀ values of 5.31 μM and 7.14 μM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.